The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, researchers from Wuhan University conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into their analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS), recurrence free survival (RSF) and progression free survival (PFS) in PCa patients. LncRNAs expression level was correlated with several vital clinical features, like tumor size, distance metastasis and histological grade. Also, down-regulation of PCAT14 was associated with the prognosis of PCa, BCR-FS, prostate cancer-specific survival and metastasis-free survival. And, the increased SChLAP1 expression could imply the worse BCR-FS and correlate with Gleason score. Conclusively, our present work demonstrated that LncRNAs transcription level might be potential prognostic markers in PCa.
The flow diagram indicated the process of study selection